Cognitive Performance in Relapsing-Remitting Multiple Sclerosis: At Risk or Impaired?

被引:4
|
作者
Altieri, Marta [1 ,2 ]
Fratino, Mariangela [1 ,2 ]
Maestrini, Ilaria [1 ]
Dionisi, Claudia [1 ,2 ]
Annecca, Rosanna [1 ,2 ]
Vicenzini, Edoardo [1 ]
Di Piero, Vittorio [1 ]
机构
[1] Sapienza Univ, Dept Human Neurosci, Rome, Italy
[2] Sapienza Univ, Multiple Sclerosis Ctr, Rome, Italy
关键词
Multiple sclerosis; Cognition; Brief International Cognitive Assessment for Multiple Sclerosis; Cognitive impairment;
D O I
10.1159/000514674
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Introduction: Since cognitive impairment (CI) occurs on average in 45% of multiple sclerosis (MS) patients, the early detection of patients "at risk" of CI is important in order to promptly apply preventive strategies. The aim of the present study was to investigate the prevalence and risk factors for CI in MS patients using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) as a screening test. Methods: During the 1-year period, CI was evaluated in 82 consecutives mild relapsing-remitting MS (EDSS <= 3.5) patients. Patients with 1 altered BICAMS test were defined "at risk." Both "at risk" and CI patients underwent an extensive neuropsychological battery. Results: We found that: (i) 23% had CI, (ii), 25% were "at risk" of CI, and (iii) 76% of the "at risk" patients were already impaired at the NP assessment. In particular, the Symbol Digit Modalities Test was the most compromised (70% of "at risk" and 79% of CI patients). Patients with CI had more frequently an EDSS >= 2.5 (p = 0.05), lower education (p = 0.05), and relapses in the last 12 months (p = 0.03). Conclusions: CI is a significant issue in MS and integration of a screening test, such as the SDMT, into routine clinical practice could be of worth to identify "at risk" patients and to promote an early therapeutic intervention.
引用
收藏
页码:539 / 543
页数:5
相关论文
共 50 条
  • [21] Depression in relapsing-remitting multiple sclerosis
    Mendes, MF
    Tilbery, CP
    Balsimelli, S
    Moreira, MA
    Barao-Cruz, AM
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2003, 61 (3A) : 591 - 595
  • [22] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [23] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [24] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [25] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [26] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [27] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [28] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [29] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [30] Longitudinal study of brain atrophy and the relationship with cognitive performance in relapsing-remitting multiple sclerosis
    Santiago, O.
    Casado, V.
    Carmona, O.
    Soriano, C.
    Pujol, J.
    Guardia, J.
    Arbiza, T.
    MULTIPLE SCLEROSIS, 2007, 13 : S226 - S226